BellBrook Labs receives NIH funding for novel approach to stimulating anti-tumor immunity
Industry News: BellBrook Labs receives NIH funding for novel approach to stimulating anti-tumor immunity 12 Mar 2021 BellBrook Labs has been awarded a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop and validate HTS assays for the discovery of small-molecule antagonists of TREX1. Immunotherapy approaches such as immune checkpoint blockade are transforming oncology. However, many patients do not respond to existing agents, and new therapeutic strategies for eliciting immune responses to tumors are badly needed. It has recently become clear that activation of the...
Source: selectscience.net